Australian vaccine development company Vaxxas has announced the appointment of Doug Cubbin as its chief financial officer.
The company said the appointment reflects its progress towards the commercialisation of its high-density microarray patch (HD-MAP) vaccine delivery technology.
Mr Cubbin has extensive experience in finance, mergers and acquisition, and business development.
Most recently, he was the group chief financial officer for Telix Pharmaceuticals, where he contributed to the growth of that company which now has a $2.3 billion market capitalisation.
He previously held senior finance positions at ANSTO and DHL.
"It's been an incredible period of growth for Vaxxas and we are pleased to be strengthening our team with the appointment of Doug Cubbin as Chief Financial Officer," said Vaxxas CEO David Hoey.
"Doug's extensive experience spans wide geographical regions, diverse market sectors, and complex regulatory environments, which brings tremendous value as we commercialise our vaccination technology platform."
Mr Cubbin added, "The opportunity Vaxxas has to introduce a novel solution to traditional vaccination methods is incredibly exciting. I'm thrilled to be joining the business at this critical juncture and look forward to seeing the company continue to grow as we work towards bringing our first vaccination patch to market."
The recruitment of Mr Cubbin follows other recent appointments, including Scott Fry as chief operating officer and Daniel Devine as chief business officer and general counsel.
